Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by mercedesmanon Jan 31, 2024 8:32pm
270 Views
Post# 35856141

Will history repeat?

Will history repeat?
  • Bagels are full of carbs


Bagelboys are full of crrap 

10 year stock charts are full of clues

Go ahead- call it up on SH 

in 2014 the stock was trading in the .25 to .40 range 

in 2015, about 18 months before the Phase 3 results, the stock 4-bagged to about $1.20. In 2016, the Phase 3 results year, a second spike took the stock to $2.07 . But alas, that trial failed to meet the primary endpoint ( largely because, with the benefit of hindsight, they didn't zero in on the right target population - mainly EAA .6 to .9, but other after the fact discoveries as well) - and so it retreated rapidly.

What might those 2015/2016 spikes have looked like if they were exceeding expectations and had met the primary end point ? $5? $7? Higher?

Now fast forward to 2024. With either 18 months or six months to go. What could happen this time around?:

  • Another spike in anticipation of the final results being released on the Phase 3b confirmatory, Tigris Trial?
  • A spike that doesn't stop after a 4X to 7X move? ( see probability discussion) 
  • A bigger spike because results are now possibly well in excess of expectations due to better targeting  ( think higher future revenues based on a much better AB ) ?

 

  • A bigger spike because of the Baxter connection, a significant distribution partner that is well thought of by the FDA?
  • A bigger spike because we have a world renowned KOL as CMO on board, who is also likely well thought of by the FDA?

 

  • A bigger spike due to EDEN and many more HA studies conducted worldwide that could widen the label /use in actual practice ? 
  • A bigger spike because of the growth in: population, Sepsis, viral infections, metabolic decease, antibiotic resistant bacteria, etc? 
hmmmmmmmm?!?!?!


MM 
 

<< Previous
Bullboard Posts
Next >>